Loading
Starton Holdings
Starton is a New Jersey company that gives existing cancer medicines continuously, through a small pump under the skin or a slow-release tablet, instead of as a daily dose. Its lead product, STAR-LLD, is a continuous low-dose form of lenalidomide being tested in multiple myeloma that has come back or stopped responding.
Also called: Starton Holdings, Inc.Starton TherapeuticsStarton Therapeutics, IncStarton Therapeutics Inc.
Overview
Starton Holdings, Inc., with principal executive offices and a laboratory in Paramus, New Jersey, filed a registration statement for its initial public offering with the SEC in 2026, with the Nasdaq symbol STA applied for. The filing describes a clinical-stage company whose platform delivers approved, off-patent medicines continuously, by ambulatory subcutaneous pump, oral controlled-release tablet or transdermal patch, to lower peak blood levels and improve tolerability, and says it is focused first on blood cancers.
Its lead programme STAR-LLD is continuous low-dose lenalidomide, the active ingredient of Revlimid, developed as a subcutaneous formulation (STAR-LLD-SC) and an oral controlled-release formulation (STAR-LLD-OCR) in parallel. The filing states that Phase 1 and 1b studies of STAR-LLD-SC in multiple myeloma are complete and that a Phase 2a study in relapsed or refractory multiple myeloma is under way; it also describes planned investigator-initiated trials with CAR-T cell therapies and T-cell engagers, the first with elranatamab supplied by Pfizer. A transdermal olanzapine patch for chemotherapy-induced nausea and vomiting is on hold. The company's operating subsidiary, Starton Therapeutics, is the sponsor of the registered trial NCT06087653.
Headquarters
Paramus, NJ, US
Scorecard
All companies#741of 1706 companies, score 3
- phase 1/2 +1
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Products
1Phase 2Immunomodulatory drug (lenalidomide) in a continuous-delivery formulation (subcutaneous pump or oral controlled release)
STAR-LLD is lenalidomide, an established myeloma medicine, given continuously at a low dose through a small pump under the skin or a slow-release tablet. Starton Holdings is testing it in multiple myeloma that has come back after earlier treatment.
Notes
- Read from the S-1/A filed on EDGAR on 28 October 2026 (business summary, cover page and corporate information) on 4 November 2026. The offering had not priced when read, so no IPO round is recorded. Founding year not read.
Connected
4cancers
fronts
drugs
Phase 2Immunomodulatory drug (lenalidomide) in a continuous-delivery formulation (subcutaneous pump or oral controlled release)
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
startontx.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/